Amanda Murphy, Chief Financial Officer

Oct. 13 | 5:00pm | AVROBIO Ballroom

Gaithersburg, MD


In-person Presentation

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. Through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its technology worldwide including with all of the top ten global biopharmaceutical companies. MaxCyte is evaluating its first autologous CAR drug candidate in mesothelin-expressing solid tumors. This product candidate, MCY-M11, employs repeat infusions of mesothelin-specific human mRNA CAR-transfected into peripheral blood mononuclear cells (PBMCs) to allow for “controlled persistence.” Early non-clinical testing has provided preliminary evidence of the anti-tumor activity of this drug.

By using this website you agree to accept our Privacy Policy and Terms & Conditions